Effects of Ketosis on Brain Function in Patients With T1DM
NCT04219709 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2024-12-18
Summary
The scientific goal of this study is to examine the effects of a ketogenic diet on hypoglycemia tolerance and brain function in people with type 1 diabetes mellitus (T1D) and to clarify the mechanistic role of ketones in this process. Glycemic management of T1D is typified by alternating periods of hyper- and hypo-glycemia. Because brain metabolism under usual conditions depends on glucose, acute hypoglycemia leads to immediate complications including impaired cognitive function and a counter-regulatory hormone response. Recurrent hypoglycemia is associated with functional and structural changes in the brain and contributes to the cognitive decline observed in individuals with diabetes. The state of nutritional ketosis (as it occurs during fasting or when following a ketogenic \[very low carbohydrate\] diet) may protect against these acute and chronic complications. As the body relies on fat metabolism, ketone bodies build up and provide an alternative fuel for the brain. Studies during hypoglycemia have shown better cognitive function and less hypoglycemia symptoms in the setting of nutritional ketosis or with ketone administration. This physiological benefit may have special relevance for people with T1D who experience hypoglycemia frequently. To date, no mechanistic studies have examined brain effects of nutritional ketosis in T1D; nor have any trials explored the potential relevance of this for diabetes care.
Conditions
- Type1diabetes
Interventions
- OTHER
-
Very low carbohydrate diet
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a fiber supplement with each meal as needed to promote digestive health, and a daily multi-vitamin, magnesium and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance. The diet composition will be as follows: 5% carbohydrate, 75% fat, 20% protein.
- OTHER
-
Standard carbohydrate diet
All meals will be delivered and participants will consume study foods exclusively. Participants will receive a daily multi-vitamin and omega-3 supplement to ascertain micronutrient sufficiency. Participants will be weighed at each study visit and the diet plan will be adjusted for satiety and weight-maintenance. The diet composition will be as follows: 50% carbohydrate, 30% fat, 20% protein.
Sponsors & Collaborators
-
Beth Israel Deaconess Medical Center
collaborator OTHER - lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-01-03
- Primary Completion
- 2026-07-31
- Completion
- 2026-07-31
Countries
- United States
Study Locations
More Related Trials
-
Residual Insulin Secretion in Patients With Type 1 Diabetes Under a Low Carbohydrate Diet or a Ketogenic Diet
NCT05536232 ·Status: UNKNOWN ·Phase: NA
-
Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus
NCT02772783 ·Status: COMPLETED ·Phase: NA
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men During Hypoglycemia
NCT00418288 ·Status: COMPLETED ·Phase: NA
-
Impact of a Low-Carbohydrate Diet in Pediatric Type 1 Diabetes
NCT03997409 ·Status: COMPLETED ·Phase: NA
-
Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.
NCT01194479 ·Status: COMPLETED ·Phase: NA
-
Ketone Monitoring in T1D: Effect of SGLT2i During Usual Care and With Insulin Deficiency
NCT05541484 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Breakfast or Omission of Breakfast in T2D
NCT01571310 ·Status: COMPLETED ·Phase: NA
-
Low Glycemic Index Diet in Patients With Type 1 Diabetes
NCT01184703 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of GLP-1 on Glucose Uptake in the Brain and Heart in Healthy Men
NCT00256256 ·Status: COMPLETED ·Phase: NA
-
The Importance of Meal Composition on Preventing Exercise-induced Hypoglycemia in People With Type 1 Diabetes.
NCT04472962 ·Status: COMPLETED ·Phase: NA
-
β-cell Function in Type 1 Diabetes May Not Be As Low As Presumed
NCT02199470 ·Status: COMPLETED
-
Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes
NCT04133922 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098 ·Status: COMPLETED ·Phase: NA
-
Intermittent Fasting in Adults With Type 1 Diabetes
NCT06134986 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118937 ·Status: COMPLETED ·Phase: PHASE4
-
GLP-1 and Hypoglycemia
NCT01858896 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance
NCT01173978 ·Status: COMPLETED ·Phase: NA
-
Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance
NCT00004419 ·Status: COMPLETED ·Phase: NA
-
Effect of GLP-1 on Glucose Metabolism in CNS Assessed by PET
NCT01185119 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
NCT04177303 ·Status: UNKNOWN ·Phase: PHASE3
-
Effects of Metreleptin in Type 1 Diabetes Mellitus
NCT01268644 ·Status: TERMINATED ·Phase: PHASE1
-
The Role of Glucose-Dependent Insulinotropic Polypeptide in the Pathological Glucose Homeostasis Of Type 1 Diabetes
NCT03734718 ·Status: COMPLETED ·Phase: NA
-
GLP-1 Analogue Treatment in Uncontrolled Type 1 Diabetic Patients
NCT01592279 ·Status: UNKNOWN ·Phase: PHASE4
-
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
NCT00862589 ·Status: COMPLETED ·Phase: NA
-
A Glucometabolic Evaluation of Patients With Idiopathic Ketotic Hypoglycemia
NCT05310292 ·Status: UNKNOWN ·Phase: NA